

Best Clinical Practices for Optimizing the Use of BTK Inhibitors for the Treatment of CLL

Presenter:



Parameswaran Venugopal, MD
Professor of Medicine
The Elodia Kehm Chair of Hematology
Director, Section of Hematology
Rush University Medical Center, Chicago, IL

JOIN YOUR COLLEAGUES AND REGISTER TODAY FOR THIS LIVE CME/CE ACCREDITED VIRTUAL WEBINAR!

Thursday, November 4, 2021

12:00 PM – 1:00 PM ET

To Register/Participate: https://us06web.zoom.us/webinar/register/WN_dRZKgLN1QOeXL5zslxt8vQ

Learning Objectives:

1. Differentiate the characteristics and clinical outcomes associated with FDA-approved BTK inhibitors
2. Analyze the safety and efficacy of BTK inhibitors for the treatment of CLL
3. Summarize emerging approaches for using BTK inhibitors to treat CLL, including combination therapy and sequencing considerations
4. Formulate individualized treatment plans for patients in the VHA/MHS/DoD system with CLL based on intrinsic characteristics of the patient, the disease, and the treatment

ACCREDITATION INFORMATION:



- Rush University Medical Center designates this live activity for a maximum of one (1) AMA PRA Category 1 Credit(s)[™]. Physicians should claim only credit commensurate with the extent of their participation in the activity.
- Rush University Medical Center designates this webinar activity for a maximum of one (1) continuing nursing education credit(s).
- This activity will fulfill Category 2 contact hour requirements for pharmacology for ANCC-certified advanced practice nurses.
- Rush University Medical Center designates this webinar activity for a maximum of one (1) continuing education unit(s) in Pharmacy.



The Association of VA Hematology/Oncology and the CLL Society are educational endorsers of this activity.

